Close Collaborators:

• The HEALED Consortium

Main Funders: 
Disruptive Technologies Innovation Fund

Active research programmes: 

Dr McCullagh is a Chief I Pharmacist ay the National Centre for Pharmacoeconomics. Here, she has led over 50 Health Technology Assessment (HTA) evaluations of health technologies. The evaluations inform the HSE reimbursement decision-making process.

Dr McCullagh has published research undertaken in HTA, including: comparative clinical-effectiveness and cost-effectiveness of drugs, evidence synthesis (for comparative-efficacy), value-of-information analysis, multiple-criteria-decision analysis, survival analysis (of immature clinical-trial data), cost of health-care and analysis of drug utilisation and prescribing & expenditure trends. Dr McCullagh is a co-applicant on a number of research grants. She is a member of the HEALED Consortium funded under the Disruptive Technologies Innovation Fund, Department of Enterprise and Innovation, Ireland. Here she is leading the HTA of novel immunotherapies for the treatment of cancers. Dr McCullagh is on the Editorial Boards of PharmacoEconomics and Frontiers in Medicine. She provides peer-review for heath-economics and clinical journals, for the Medical Research Council, UK and the Veni Scheme, Netherlands Organization for Scientific Research. She is on the ISPOR Europe Research Programme Committee.